What is HC Wainwright’s Forecast for FULC FY2029 Earnings?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein expects that the company will earn ($0.95) per share for the year. HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $3.37 on Thursday. Fulcrum Therapeutics has a 1-year low of $2.86 and a 1-year high of $13.70. The business’s 50 day moving average is $4.12 and its two-hundred day moving average is $4.61. The stock has a market capitalization of $181.77 million, a P/E ratio of -10.87 and a beta of 2.03.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03).

Institutional Trading of Fulcrum Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Mackenzie Financial Corp increased its stake in shares of Fulcrum Therapeutics by 412.5% during the fourth quarter. Mackenzie Financial Corp now owns 118,025 shares of the company’s stock valued at $555,000 after buying an additional 94,997 shares during the period. Woodline Partners LP grew its position in Fulcrum Therapeutics by 110.3% during the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock worth $6,629,000 after purchasing an additional 739,713 shares during the last quarter. Suvretta Capital Management LLC lifted its position in Fulcrum Therapeutics by 182.3% during the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock worth $15,691,000 after acquiring an additional 2,155,675 shares during the period. Shay Capital LLC lifted its stake in Fulcrum Therapeutics by 4.2% during the 4th quarter. Shay Capital LLC now owns 301,464 shares of the company’s stock valued at $1,417,000 after acquiring an additional 12,227 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 224.0% in the 4th quarter. Millennium Management LLC now owns 76,123 shares of the company’s stock valued at $358,000 after buying an additional 52,628 shares during the period. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.